The World Health Organization (WHO) is to provide funding to spin-out company, Vaxxas, so it can develop the NanopatchTM for polio vaccination. WHO will fund pre-clinical studies and the development of good manufacturing practices. Following the successful completion of this research, and all subsequent necessary clinical development and regulatory approvals, Vaxxas would have the opportunity to supply Nanopatches to help secure a lasting polio-free world. The development of the NanopatchTM has depended on AMMRF microscopy.
Polio was one of the most dreaded childhood diseases of the 20th century, resulting in limb disfigurement and irreversible paralysis in tens of millions of cases. As recently as 1988, more than 350,000 cases occurred every year in more than 125 endemic countries. Concerted efforts to eradicate the disease have reduced incidence by more than 99%, and efforts are being intensified to eradicate the remaining strains of transmission once and for all.